Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Volunteers

Trial Profile

Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs JNJ 61187191 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Crucell Holland
  • Most Recent Events

    • 22 Aug 2016 Status changed from recruiting to completed.
    • 25 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top